Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28946384 | 0.88 | RXRA (0.41) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL508718 | 0.86 | RXRA (0.44) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL12295637 | 0.85 | RXRA (0.43) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL19471078 | 0.85 | RXRA (0.43) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL22897584 | 0.80 | RXRA (0.40) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL19120213 | 0.76 | RXRA (0.40) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL8087729 | 0.76 | RXRA (0.40) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL31465996 | 0.76 | HTT (0.47) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL19121178 | 0.76 | MAPT (0.42) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL29266953 | 0.76 | RXRA (0.37) | RXRAGRIN1GRIN2BL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | RXRA 2473/4885GRIN1 3584/4885GRIN2B 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.